- CyPath® Lung detects Stage 1A lung cancer in high-risk patient after inconclusive imaging results.
- bioAffinity Technologies (BIAF, Financial) reports significant cost savings when CyPath® Lung is used for indeterminate lung nodules.
- CyPath® Lung demonstrates 92% sensitivity, 87% specificity, and 88% accuracy in early lung cancer detection.
bioAffinity Technologies, Inc. (BIAF) has announced a successful case study where its noninvasive CyPath® Lung test detected Stage 1A lung cancer in a high-risk patient following inconclusive imaging. The patient, a 70-year-old female with a significant smoking history and COPD, initially showed a low risk of malignancy based on PET imaging and risk model probability. However, the CyPath® Lung test results indicated a high probability of cancer, leading to successful surgical intervention.
CyPath® Lung utilizes advanced flow cytometry and AI to analyze patient sputum for cancer indicators, boasting a 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in high-risk patients. The case underscores the test’s value in providing critical diagnostic clarity when other methods fall short, as highlighted by the company’s Chief Medical Officer, Dr. Gordon Downie, and bioAffinity Technologies’ CEO, Maria Zannes.
Additionally, the use of CyPath® Lung has shown potential economic benefits. A study estimated that deploying this test for patients with small pulmonary nodules could have resulted in Medicare savings of $370 million, or $2,733 per patient, in 2022. The savings could increase to $6,460 per patient if covered by private insurance. The test is currently reimbursed by Medicare and various commercial payers, and is available on the Federal Supply Schedule for veterans and active-duty military personnel.
bioAffinity Technologies continues to innovate in the noninvasive diagnostics space with its focus on early-stage cancer detection and broad-spectrum cancer treatments. For further details on CyPath® Lung and company developments, visit the bioAffinity Technologies website.
